Like Ras, farnesylation of the IP (prostacyclin receptor) is required for its efficient intracellular signalling, and hence the IP represents a potential target for inhibition by FTIs [FTase (farnesyl protein transferase) inhibitors]. Herein, the effect of SCH66336 on the isoprenylation and function of the human and mouse IPs overexpressed in human embryonic kidney 293 cells, and by the IP endogenously expressed in human erythroleukaemia cells, was investigated. SCH66336 yielded concentration-dependent decreases in IP-mediated cAMP generation (IC 50 0.27-0.62 nM), [Ca 2+ ] i mobilization (IC 50 26.6-48.3 nM) and IP internalization, but had no effect on signalling by the non-isoprenylated β 2 adrenergic receptor or β isoform of the TP (prostanoid thromboxane A 2 receptor). Additionally, SCH66336 impaired IP-mediated crossdesensitization of TPα signalling (IC 50 56.1 nM) and reduced farnesylation of the molecular chaperone protein HDJ-2 (IC 50 3.1 nM). To establish whether farnesylation of the IP is inhibited and/or whether its 'CaaX motif' might undergo alternative geranylgeranylation in the presence of SCH66336, a series of chimaeric Ha (Harvey)-Ras fusions were generated by replacing its CaaX motif (-CVLS) with that of the IP (-CSLC) or, as controls, of Ki (Kirsten)-Ras 4B (-CVIM) or Rac 1 (-CVLL). Whereas SCH66336 had no effect on Ha-Ras CVLL isoprenylation in vitro or in whole cells, it supported alternative geranylgeranylation of Ha-Ras CVIM , but completely impaired isoprenylation of both HaRas CVLS and Ha-Ras CSLC . These data confirm that the -CSLC motif of the IP is a direct target for inhibition by the FTI SCH66336, and in the presence of strong FTase inhibition, the IP does not undergo compensatory geranylgeranylation.
INTRODUCTION
Ras guanine-nucleotide-binding proteins act as molecular switches, transducing an array of extracellular growth and differentiation signals from cell-surface receptors to the nucleus [1] . Mutations in codon 12, 13 or 61 of one of the three ras genes, i.e. Ha (Harvey)-ras, N (neuronal)-ras or Ki (Kirsten)-ras, encode a constitutively activated protein that transforms cells to a malignant phenotype by providing uninterrupted growth signals [2, 3] . In mammalian cells, Ras becomes biologically active following a series of post-translational modifications, which allow for its subsequent localization to the inner face of the plasma membrane [4] . The first modification is initiated by the formation of a stable thioether bond between a cysteine located in a distinct C-terminal motif (CaaX) and a hydrophobic isoprenyl (farnesyl or geranylgeranyl) group derived from their pyrophosphate intermediates of the cholesterol biosynthetic pathway [4] . Farnesylation, catalysed by FTase (farnesyl protein transferase), is directed by a C-terminal CaaX motif, where 'C' is cysteine, 'a' is usually an aliphatic residue, and 'X' is typically methionine, serine, glutamine, cysteine or alanine. Where 'X' represents a leucine or isoleucine, the protein becomes geranylgeranylated, catalysed by GGTase 1 (geranylgeranyl protein transferase 1) [4] . Proteolytic cleavage to remove the 'aaX' residues, followed by carboxylmethylation of the farnesyl/geranylgeranyl-cysteine residue, completes the CaaX-directed series of post-translational modifications [4] .
Given that oncogenic mutations of the ras gene occurs in over 30 % of all known human cancers, the Ras signalling pathway represents a major therapeutic target in malignant transformation [1] . Indeed, the improved understanding of the molecular mechanisms of Ras expression, processing, activation and action on downstream effectors has promulgated the development of novel agents designed to target this critical aberrant pathway [2] . Of these, the FTIs (FTase inhibitors) have shown most potential, having reached phase III clinical trial status [5] . By inhibiting farnesylation of Ras, FTIs prevent its subsequent obligate localization to the plasma membrane, and hence impair transduction of its proliferative signals [6] . SCH66336 (Ionafarnib ® ; Sarasar ® ) was the first FTI to undergo clinical development [5] . A non-peptidyl, non-thiol tricyclic FTI, SCH66336 has demonstrated significant biological and clinical activity in a range of malignancies and solid tumours [5, 6] . Confirmation of biological efficacy has been demonstrated further with surrogate markers in various clinical trials: SCH66336 inhibited prelamin A farnesylation in buccal mucosa cells at clinically relevant doses, while an 11-50 % increase in non-farnesylated molecular chaperone protein HDJ-2 was observed in surgical specimens from patients treated with 100, 200 or 300 mg SCH66336 twice daily for 8-14 days [5] .
Although SCH66336 is selective in in vitro assays, there is currently insufficient published data to confirm that FTIs do not interfere, adversely or otherwise, with farnesylation and function of other unidentified proteins. In the present study, we have examined the effect of SCH66336 on farnesylation of one such protein, the IP (prostacyclin receptor). IP mediates the action of prostacyclin [prostaglandin (PG)I 2 ], a labile cyclo-oxygenasederived metabolite of arachidonic acid [7] . Prostacyclin plays a prominent role in vascular haemostasis, acting as a potent inhibitor of platelet aggregation and as a vasodilator [7] . Perturbations in prostacyclin and/or IP signalling have been implicated in the pathogenesis of a number of disorders, including ischaemic heart disease, atherosclerosis, renal failure and systemic and pregnancyinduced hypertension [7] [8] [9] [10] . The finding that both the human (h) and mouse (m) IP are farnesylated, and that this modification is absolutely required for efficient receptor-effector coupling, raises the possibility that SCH66336 may inadvertently interfere with IP signalling, and hence IP function [11, 12] . Thus the overall aim of the present study was to investigate the effect of SCH66336 on farnesylation and intracellular signalling by hIP and mIP expressed in mammalian cells with the view to ascertaining whether the IP is a likely therapeutic target for FTI inhibition, and to assess the potential implications thereof. In addition, we sought to examine whether the 'CAAX' motif of the IP is solely a substrate for farnesylation, or whether it undergoes alternative geranylgeranylation in the presence of SCH66336. ) were purchased from American Radiolabeled Chemicals Inc. Isoproterenol was purchased from Sigma. Fura 2/AM (fura 2 acetoxymethyl ester) and U46619 was purchased from Calbiochem. Rabbit reticulocyte translation system (minus methionine), T7 RNA polymerase, RNasin and all restriction endonucleases were purchased from Promega Corp. Taq DNA polymerase, the chemiluminescence Western detection kit, and rat monoclonal 3F10 anti-HA (haemagglutinin) peroxidase-conjugated antibody were purchased from Roche. Horseradish peroxidase-conjugated goat anti-mouse IgG was from Santa Cruz Biotechnology. Mouse monoclonal 101R anti-HA antibody was obtained from BabCO. Anti-HDJ2 was from Neomarkers. Secondary FITC-conjugated anti-mouse IgG serum was purchased from Jackson Immunoresearch Laboratories, Inc. Oligonucleotides were synthesized by Genosys Biotechnologies. All other reagents were A. R. or molecular biology grade, and were used without further purification.
EXPERIMENTAL

Cell culture and transfections
Human embryonic kidney (HEK).mIP, HEK.hIP, HEK.TPα [where 'TPα' is prostanoid thromboxane A 2 (TXA 2 ) receptor] and HEK.TPβ cells, stably overexpressing HA-epitope-tagged forms of the wild-type mIP and hIP or the human TPα and β isoforms respectively, have been described previously [11, 13] . HEK-293 cells were transiently transfected with pHM-or pCMVbased vectors using the calcium phosphate/DNA co-precipitation procedure [11, 13] and were harvested 48 h post-transfection.
To generate a mammalian cell line overexpressing the β 2 AR (β 2 adrenergic receptor), a HindIII-EcoRI subfragment encoding the full-length cDNA for the human β 2 AR was subcloned from the plasmid pTF3 (A.T.C.C.) into a HindIII-EcoRI site of pHM6 (Roche) to generate pHM:β 2 AR. Thereafter, HEK.β 2 AR cell lines stably overexpressing the β 2 AR receptor in HEK-293 cells were established, using pHM:β 2 AR, and characterized essentially as described previously [11, 13] .
Subcloning and site-directed mutagenesis of the 'CaaX motif' of Ras
The plasmid pHM:Ras was constructed by subcloning the fulllength coding sequence for wild-type human Ha-Ras (Ha-Ras WT ) from pCMV5:Ras [14] respectively, using the mutator oligonucleotide 5 -dAGA GGT ACC TTA CAT AAT CAC ACA CTT GCA GCT-3 (antisense primer).
In each case, PCR mutagenesis was performed using the oligonucleotide 5 -dGAG AAG CTT G ATG ACG GAA TAT AAG CTG GTG-3 as sense primer (whereby the sequence corresponding to the initiation codon is underlined) in combination with the specified mutator oligonucleotide, as antisense primer, using the plasmid pCMV:Ras [14] as a template. Thereafter, PCR-generated products were subcloned in-frame into the [11] . β 2 AR and TP radioligand assays were performed on whole cells, as described previously [13, 15] . Where specified, cells were pre-incubated with either 1 µM SCH66336 (added from 1000-fold-concentrated stocks diluted in 0.0001 % DMSO) or with the corresponding volume of vehicle (DMSO) for 16 h before harvesting.
Measurement of SCH66336-induced cytotoxicity
Possible cytotoxic effects of SCH66336 were evaluated by measuring LDH (lactate dehydrogenase) release following exposure of cells for 24 h with 1 nM, 20 nM and 1000 nM SCH66336 using a Cytotox 96 Non-Radioactive Cytotoxicity assay kit (Promega), essentially as described by the manufacturer. 
Measurement of cAMP
To investigate the effect of SCH66336 on agonist-mediated cAMP generation, cells were pre-incubated in the presence or absence of SCH66336 (10 nM) for 16 h before harvesting. For concentration-response studies, cells were pre-incubated for 16 h in the presence of SCH66336 (0-10 nM). For time-course assays, cells were pre-incubated for 0-24 h in the presence of SCH66336 (5 nM). Thereafter, non-viable cells were removed, and cAMP assays were preformed as described previously [11] . ] i mobilization in fura 2/AM-preloaded cells was carried out essentially described as previously [11] . Cells were pre-incubated for 16 h with either SCH66336 (1000 nM) or with the vehicle, 0.0001 % DMSO. For concentration-response studies, cells were pre-incubated with SCH66336 (0-1000 nM) for 16 h. In separate experiments, to examine the concentration effect of SCH66336 on IP-mediated counter-regulation of TP-mediated signalling, HEK.TPα cells and HEK.TPβ cells, transiently transfected with pCMV:Gα q , were pre-incubated in the presence or absence of SCH66336 (1000 nM) for 16 h. For concentrationresponse studies, cells were pre-incubated with SCH66336 (0-1000 nM) for 16 h. Thereafter, [Ca 2+ ] i mobilization in fura 2/AM-preloaded cells was measured essentially as described previously [11] .
Immunofluorescence microscopy
Immunofluorescence analysis was performed essentially as described previously [12] . Cells were pre-incubated for 24 h with either SCH66336 (1000 nM) or with the vehicle, 0.0001 % DMSO. Thereafter, cells were stimulated with cicaprost (1 µM; 4 h) or with vehicle (Tris-buffered saline), serving as a control. Immunofluorescent images, captured with the appropriate FITC filter, were monitored using an Axioplan 2 Fluorescent Microscope (Zeiss Vision GmbH, Cologne, Germany).
Agonist-induced IP internalizations
For quantification of agonist-induced IP internalization, ELISAs were performed essentially as described previously [12] . Cells were incubated with 1 µM SCH66336 or with vehicle (0.0001 % DMSO) for 24 h. Internalizations of HA-tagged IP receptors were quantified as the mean percentage (%) of cellsurface IP in agonist-treated cells relative to vehicle (non-treated) cells + − S.E.M., where control, vehicle-treated cells were assigned a value of 100 %.
Immunoblot analysis of HDJ-2 isoprenylation
To investigate the effect of SCH66336 on HDJ-2 isoprenylation, cells were incubated with SCH66336 (0-10 nM) or with the vehicle (0.0001 % DMSO) for 24 h. For time-dependent-response studies, cells were incubated with SCH66336 (5 nM) or with the vehicle (0.0001 % DMSO) for 24 h. Thereafter, cells were harvested and aliquots of whole-cell protein (25 µg) were analysed for HDJ-2 expression essentially as described previously [16] . Quantification of farnesylated and non-farnesylated HDJ-2 protein fractions was performed by densitometric scanning using a GelWorks 1D Intermediate UVP gel documentation system.
Percentage inhibition of HDJ-2 farnesylation was determined by comparing the signal in the non-farnesylated band with the overall intensities of farnesylated plus non-farnesylated bands. The levels of non-farnesylated protein in vehicle-treated cells were assigned a value of zero.
In vitro transcription, translation and isoprenylation
Prior to in vitro transcription, pHM:Ras WT , pHM:Ras CSLC , pHM: Ras SSLC , pHM:Ras CVLL and pHM:Ras CVIM plasmids were linearized by digestion with EcoRI. The linearized plasmids (4 µg) were transcribed with T7 RNA polymerase as previously described [14] . In vitro translation of the RNA transcripts was performed in a methionine-deficient rabbit reticulocyte lysate system (Promega) according to manufacturer's recommendations. Standard reactions (25 µl [14] . Proteins from each reaction were subjected to SDS/PAGE, followed by electroblotting on to PVDF membranes. Blots were soaked in Amplify (Amersham Biosciences) for 30 min, followed by autoradiography using Kodak Xomat XAR film at − 70
• C for at least 21 days for 3 H exposures, or for 16 h for [
35 S]methionine exposures.
In vivo isoprenylation in whole cells
To investigate the ability of SCH66336 to interfere with isoprenylation of Ha-Ras WT , Ha-Ras CSLC , Ha-Ras SSLC , Ha-Ras CVLL and Ha-Ras CVIM in vivo, metabolic labelling of whole cells was performed essentially as described previously [11] . Cells were pre-incubated for 16 h with either 250 µCi [ 3 H]MVA plus 1 µM SCH66336, or with 250 µCi [ 3 H]MVA plus an equivalent volume of the drug vehicle (0.0001 % DMSO). Thereafter, cells were harvested and aliquots of whole cell protein (60 µg) were resolved by SDS/PAGE and electroblotted on to PVDF membranes. The remaining protein from each transfection (≈ 500 µg) was subjected to immunoprecipitation using the anti-(HA 101R) serum, as described previously [11] . Blots were then permeated in Amplify (Amersham Biosciences) and subjected to fluorography, as described previously [11] .
Data analysis
Statistical analysis was carried out using the unpaired Student's t test using the GraphPad Prism V2.0 program (GraphPad Software Inc., San Diego, CA, U.S.A.). P values 0.05 were considered to indicate a statistically significant difference.
RESULTS
SCH66336 is a selective FTase inhibitor undergoing clinical trials as a chemotherapeutic agent for the treatment of a variety of solid tumours [5] but, to date, has not yet been extensively tested against certain other proteins known to undergo farnesylation, such as the IP. Thus in the present study we investigated the potential effects of SCH66336 on isoprenylation and function of hIP and mIP stably expressed in HEK-293 cells, or by the hIP endogenously expressed in HEL92.1.7 ('HEL', human erythroleukaemia) cells.
Initially, the potential effect of SCH66336 on the cell viability of HEK-293 and HEL cells cultured in a range of SCH66336 concentrations was evaluated. While the level of SCH66336-induced Thereafter, the effect of SCH66336 on intracellular signalling by the IP expressed in HEK.hIP and HEK.mIP cells, and in HEL cells was investigated by examining its effect on agonist-induced cAMP generation in response to the selective IP agonist cicaprost [7] . As a control, the effect of SCH66336 on cAMP generation by the non-isoprenylated G s /adenylate cyclase-coupled β 2 AR in response to stimulation of HEK.β 2 AR cells with isoproterenol was also examined. Whereas HEK.hIP and HEK.mIP cells exhibited significant cicaprost-induced increases in cAMP, pre-incubation of those cells with 10 nM SCH66336 for 16 h reduced cAMP generation to levels that were not significantly different from those generated by the non-transfected parental HEK-293 cells ( Figure 1A ). From concentration-response studies, IC 50 values for SCH66336 in HEK.hIP ( Figure 1B ) and HEK.mIP ( Figure 1C ) cells were determined to be 0.27 nM and 0.43 nM respectively, while the extent of maximal inhibition at 10 nM SCH66336 was found to be 71.4 + − 7.1 % (P 0.0001) and 74.4 + − 9.4 % (P 0.0001) for hIP and mIP respectively ( Figures 1A-1C) . Consistent with that observed in the HEK.hIP and HEK.mIP cell lines, agonist stimulation of hIP endogenously expressed in HEL cells exhibited significant fold increases in cicaprost-induced cAMP generation over basal levels ( Figure 1A) . Moreover, preincubation of HEL cells with SCH66336 (16 h) significantly reduced cicaprost-induced cAMP generation in a concentrationdependent manner (IC 50 0.62 nM; Figures 1A and 1D ). From concentration-response studies, an IC 50 of 0.62 nM SCH66336 was determined, while the extent of maximal inhibition of hIP signalling at 10 nM SCH66336 was 80.3 + − 1.2 % (Figures 1A and  1D ; P 0.0001). Whereas stimulation of the control HEK.β 2 AR cells with isoproterenol (10 µM) produced a 6.9 + − 0.21-fold increase in cAMP generation over basal levels, in contrast with those studies involving the IPs, pre-treatment of HEK.β 2 AR cells with SCH66336 did not significantly affect the levels of isoproterenol-induced cAMP generation throughout the range of SCH66336 concentrations utilized (Figures 1A and 1E ; P 0.5).
The effect of SCH66336 on IP-mediated [Ca 2+ ] i mobilization
Although the IP is mainly coupled to Gs/adenylate cyclase activation, it also exhibits efficient coupling to G q /PLCβ (phospholipase Cβ) activation, with concomitant rises in [Ca 2+ ] i in certain cell types [11, 12] . Hence, in the present study, we extended our investigations to examine the effect of SCH66336 on cicaprost-induced [Ca 2+ ] i mobilization by hIP and mIP stably overexpressed in HEK-293 cells and in HEL cells. As a control for a nonisoprenylated G q /PLCβ-coupled GPCR (G-protein-coupled receptor), the effect of SCH66336 on agonist-induced [Ca 2+ ] i mobilization by the β isoform of TP (TPβ) was investigated. Consistent with previous reports [11, 12, 15] Figure 2B ) and 26.6 nM SCH66336 ( Figure 2D ), respectively. Moreover, the extent of maximal inhibition using 1 µM SCH66336 was 62.9 + − 3.0 % and 62.0 + − 5.5 % for the hIP and mIP respectively, relative to that mobilized in the absence of SCH66336 (Figures 2A and 2C) . 
The effect of SCH66336 on ligand binding properties of the IP
To exclude the possibility that the observed reductions in IP-mediated signalling might be indirect, such as due to an overall reduction in the level of IP expression rather than due to a functional impairment of IP coupling to Gα s /adenylate cyclase or Gα q /PLCβ, the effect of SCH66336 on the radioligand binding properties of the hIP and mIP was investigated ( Table 2 ).
The effect of SCH66336 on IP agonist-mediated internalization
The IP has been widely reported to undergo rapid agonist-induced internalization and desensitization following activation, and such desensitizations are believed to represent important mechanisms whereby the responses to the potent autocoid prostacyclin is dynamically regulated [17] . Through the generation of an isoprenylation-defective hIP SSLC , we have recently established that, while both the hIP and hIP SSLC undergo agonist-induced internalization, the kinetics and extent of hIP SSLC internalization was impaired relative to that of wild-type hIP, implying that farnesylation of the IP is also required for efficient agonist-induced IP desensitization and internalization [12] . Thus, in the current study, the possible effects of SCH66336 on cicaprost-induced IP internalization were investigated, as assessed by indirect immunofluorescence microscopy and ELISA. Initially, immunofluorescence microscopy was performed on HEK.hIP cells and, as a control, on HEK-293 cells under non-permeabilizing conditions ( Figure 3A) . The hIP was abundantly expressed on the plasma membrane of HEK.hIP cells, as evidenced by strong immunostaining of cells (Figure 3Ai ). In contrast, the control HEK-293 cells showed no immunofluorescent staining (Figure 3Aiv ). Consistent with previous reports [12] , the hIP underwent cicaprost-induced (1 µM for 4 h) internalization, as evidenced by a decrease in surface expression of the HA-epitope-tagged hIP compared with that of vehicle-treated cells (Figure 3Aii ). However, pre-incubation of HEK.hIP cells with SCH66336 (1 µM for 24 h) significantly reduced the extent of cicaprost-induced hIP internalization, as evidenced by the strong immunofluorescent staining on the plasma membrane (Figure 3Aiii) . Thereafter, the effect of SCH66336 (1 µM for 24 h) on cicaprost-induced IP internalization was quantified further using an ELISA-based internalization assay [12] . Consistent with previous reports [12] , stimulation of hIP with cicaprost induced a time-dependent internalization of the receptor, as monitored by the loss of surface expression of HA-epitope-tagged IP on the plasma membrane in non-permeabilized HEK.hIP cells (Figure 3B ; 53.5 + − 1.6 % cell-surface hIP receptor remaining relative to vehicle-treated cells following a 4 h incubation with cicaprost). However, pre-incubation of the HEK.hIP cells with SCH66336 (1 µM for 24 h) significantly impaired cicaprost-induced internalization of the hIP ( Figure 3B ; 82.3 + − 1.6 % cell-surface hIP receptor remaining relative to vehicle-treated cells following 4 h; P < 0.0001).
The effect of SCH66336 on IP-mediated desensitization of TP signalling
We have previously established that the TPα, but not the TPβ, isoform of TP is subject to IP-induced desensitization/counterregulation of signalling that occurs through a mechanism involving direct PKA (cAMP-dependent protein kinase) phosphorylation of TPα within its unique C-tail domain, whereby Ser 329 was identified as the target residue for PKA phosphorylation and receptor desensitization [13] . Thus, in view of its inhibitory effect on IP signalling reported herein, we sought to investigate the effect of SCH66336 on IP-mediated desensitization or counter-regulation of TP receptor responses. Thus, to this end, we examined the ability SCH663366 to regulate cicaprost-induced desensitization of TPα-and, as a control, TPβ-mediated increases in [Ca 2+ ] i mobilization in response to their stimulation with U46616. Consistent with previous reports [13] Figure 4D) , and had no effect on the ability of cicaprost to affect TPβ-mediated [Ca 2+ ] i mobilization ( Figures 4D and 4F) . Thus U46619-induced signalling by HEK.TPβ cells was unaffected, irrespective of pre-incubation of cells in the absence or presence of SCH66336 ( Figures 4D  and 4F ).
The effect of SCH66336 on HDJ-2 isoprenylation
The molecular chaperone protein HDJ-2 undergoes farnesylationdependent processing, and displays a mobility shift between the non-farnesylated (49 kDa) and farnesylated (45 kDa) species respectively, such as that displayed when farnesylation is impaired in the presence of FTIs [18] . Thus detection and measurement of the relative abundance of the farnesylated and non-farnesylated forms of HDJ-2 through immunoblot analysis is widely reported to represent a convenient method to (a) assess the potencies of FTI, and (b) in the present study, should allow for a comparison between the relative inhibitory effects of SCH66336 on the isoprenylation of the IP to that of the HDJ-2. Analysis of wholecell lysates prepared from HEK-293 cells indicated the abundant expression of HDJ-2 protein in that cell line and that, in the absence of the FTI, it is almost exclusively found in its fully processed, isoprenylated form, with no detectable expression of the slower migrating non-farnesylated species ( Figure 5A ). Following 24 h incubation of HEK-293 cells with SCH66336 (0-10 nM), there was a concentration-dependent increase in the accumulation of non-farnesylated species, and a co-ordinated reduction in the level of the faster migrating, farnesylated species ( Figures 5A and 5C ). An IC 50 value for inhibition of HDJ-2 farnesylation was 3.1 nM SCH66336, whereas the minimum inhibitory concentration for the appearance of the slower migrating non-farnesylated form was detected at 0.8 nM (Figures 5A  and 5C ). To determine the pre-incubation time required for SCH66336 to inhibit HDJ-2 farnesylation, a time course assay was performed whereby HEK-293 cells were incubated in the presence of SCH66336 (5 nM) for 0-24 h (Figures 5B and 5D ). Data generated showed that SCH66336 significantly affected the mobility of HDJ-2 after 4 h, and continued to 24 h ( Figure 5B ).
The effect of SCH66336 on protein isoprenylation in vitro
Whereas all four Ras proteins serve as efficient substrates for FTase, readily undergoing farnesylation both in vitro and in vivo [4] , numerous studies have demonstrated that, in the presence of FTIs, Ki-Ras 4A, Ki-Ras 4B and N-Ras, but not Ha-Ras, may become alternatively geranylgeranylated [19] [20] [21] . Thus, in order to establish whether farnesylation of the CaaX motif of the IP with the sequence -CSLC is inhibited by SCH66336, and to establish whether this motif is subject to alternative geranylgeranylation in the presence of SCH66336, similar to that seen with N-Ras, KiRas 4A and Ki-Ras 4B, we generated a series of chimaeric Ha-Ras mutants in which we directly replaced the -CaaX motif sequence of wild-type Ha-Ras (-CVLS, corresponding to residues 186-189) with that of IP (-CSLC) to generate Ha-Ras CSLC . Moreover, as controls, other chimaeric Ha-Ras mutants were created by directly replacing the -CaaX motif sequence of Ha-Ras WT (-CVLS, corresponding to residues 186-189) with: (i) that of the nonisoprenylated IP control -SSLC sequence, to generate Ha-Ras SSLC ; (ii) that of the geranylgeranylated Rac 1 -CVLL sequence, to generate Ha-Ras CVLL ; or (iii) that of the alternatively isoprenylated Ki-Ras 4B -CVIM sequence, to generate Ha-Ras CVIM . This experimental approach of replacing the CAAX motif of Ha-Ras with those of other isoprenylated proteins first allows for a direct comparison between the various -CAAX motifs under study as substrates for isoprenylation, either in vitro or in whole cells (in vivo). Secondly, in the case of the IP, this approach is necessitated by the inability to translate the seven-transmembrane receptor in an in vitro system and, thirdly, by the difficulty in expressing the IP at sufficiently high levels in mammalian systems to facilitate its efficient metabolic labelling with [ 3 H]MVA in vivo in intact cells which may, in turn, obscure interpretation of data generated in the presence of SCH66336.
Initially, we employed an in vitro assay approach to directly compare the effect of SCH66336 on the isoprenylation and farnesylation of Ha-Ras and its variants. Figure 6A, lanes 1-5) , whereas the level of endogenous protein synthesis in the absence 
DISCUSSION
FTIs were originally developed to block constitutive signalling by mutant Ras proteins [22] . However, current evidence suggests that FTIs have broad anticancer action, an activity that in some instances is not necessarily correlated with the presence of mutated ras oncogenes [22] [23] [24] . Identification of the critical targets or other potential effects of FTI action is the key outstanding question in gaining full knowledge as to the true efficacy of these drugs in vivo. SCH66336 is an orally active tricyclic compound that has entered phase II/III clinical trials for the treatment of various cancers, including pancreatic cancer, glioblastoma and solid tumours [5, 6] . In addition to its FTase inhibition of Ras, data herein demonstrate that SCH66336 exhibits substantial inhibition of IP function through impairment of IP farnesylation and intracellular signalling. Along with nitric oxide (NO), prostacyclin acts synergistically on smooth-muscle cells, leucocytes and platelets, playing a major role in maintaining vascular integrity and blood fluidity [7] . Moreover, prostacyclin is a potent pro-inflammatory mediator and has also been proposed as an anticancer prostanoid, given its antiproliferative, anti-apoptotic and anti-metastatic nature/properties seen in experimental tumour models [25] [26] [27] [28] . Although the role of prostacyclin in angiogenesis has not been fully examined, there is evidence for both pro-and anti-angiogenic effects [29] [30] [31] [32] [33] . The IP is primarily coupled to G s -dependent activation of adenylate cyclase, but can also couple to G q /PLCβ [34] . The IP appears to be unique among the GPCRs in that it undergoes farnesylation and palmitoylation, post-translational modifications that are critical for IP function [11, 12, 15, 35] .
Given the ambiguity surrounding the mechanism of action of the FTIs and their true targets [5, 23, 24] , the current study examined the effect of SCH66336 on signalling by both the hIP and mIP stably expressed in HEK-293 cells, and by the hIP endogenously expressed in HEL cells. Pre-treatment of HEK.hIP, HEK.mIP and HEL cells with SCH66336 (1 µM) for 16 h reduced hIP-and mIP-mediated cAMP generation to approx. 28.6 + − 7.1 %, 25.7 + − 9.4 % and 19.1 + − 1.2 % respectively, whereas 1 µM SCH66336 reduced hIP-, mIP-and HEL-mediated [Ca 2+ ] i mobilization to 37.1 + − 3 %, 38.0 + − 5.5 % and 26.8 + − 7.1 % respectively. Moreover, these reductions in IP-mediated cAMP generation and [Ca 2+ ] i mobilization occurred in a concentrationdependent manner. Conversely, SCH66336 had no effect on [ 3 H]-iloprost binding, excluding the possibility that the reduction in IP function was attributable to an overall decrease in IP expression. No significant decreases in β 2 AR-mediated cAMP generation or TPβ-mediated [Ca 2+ ] i mobilization occurred, confirming that the reductions elicited by SCH66336 are targeted to the IP itself and not to another component of the signalling system. Whereas SCH66336 (1 µM) also significantly reduced the extent and kinetics of cicaprost-induced IP internalization, from concentration-response studies it was shown that SCH66336 at concentrations lower than 0.1 µM did not yield significant reductions in IP internalization (results not shown). Hence, comparing our data herein, it is evident that IP-mediated intracellular signalling (cAMP generation and [Ca 2+ ] i mobilization) are substantially more sensitive to inhibition by SCH66336 than is agonist-mediated IP internalization. It is, however, indeed noteworthy that the circulating plasma concentrations in humans taking 200 mg of SCH66336 twice daily achieve levels greater than 1 µM [36] , and therefore represent levels substantially higher than those required to inhibit IP signalling and agonist-induced IP internalization in whole cells.
Cross-desensitization or counter-regulation of responses is widely documented to occur between the anti-aggregatory adenylate cyclase/PKA system elicited by prostacyclin and the proaggregatory PLCβ/PKC system elicited by TXA 2 in platelets and vascular smooth muscle [8, 13, 37] . More specifically, the TPα, but not the TPβ, isoform of the human TXA 2 receptor undergoes IP-mediated desensitization through direct PKA phosphorylation of TPα within its C-tail domain [13] . Given the central role of the latter counter-regulation between IP and TPα signalling, coupled with the finding that SCH66336 is a potent inhibitor of IP function, we next examined the effect of SCH66336 on IP-mediated desensitization or counter-regulation of the TP responses. Consistent with previous studies, both TPα The ubiquitously expressed HDJ-2 is farnesylated and undergoes a mobility shift upon treatment with FTI [18] . Thus the detection and relative abundance of the farnesylated and nonfarnesylated forms of HDJ-2 through immunoblot analysis offers a convenient method to assess SCH66336 potency and, herein, allowed us to compare the relative inhibitory effects of SCH66336 on the isoprenylation of the IP to that of HDJ-2. Given that the IC 50 for inhibition of cicaprost-induced cAMP generation reported herein ranged from 0.27 to 0.62 nM SCH66336, and the IC 50 for inhibition of HDJ-2 isoprenylation was 3.07 nM, it is indeed apparent that IP isoprenylation and primary signalling (agonist-induced cAMP generation) is 5-10-fold more sensitive to SCH66336 inhibition than is HDJ-2.
FTIs offer an appealing paradigm for the rational design and development of novel anticancer agents, such as SCH66336, as they exploit the necessary farnesylation of Ras, and so inhibit its oncogenic potential [5] . However, while all four Ras proteins are efficient substrates for FTase [4] , numerous studies have demonstrated that, in the presence of FTIs, N-Ras, Ki-Ras 4A and Ki-Ras 4B may become alternatively geranylgeranylated [19] [20] [21] 24] . Nonetheless, FTI treatment can significantly inhibit the growth of tumours containing Ki-Ras mutations [38] [39] [40] , suggesting either that other farnesylated cellular protein(s) distinct from Ras may also play a role in the biological consequences of FTI treatment [41] , or that farnesylated and geranylgeranylated Ki-Ras may function differently [24] . Other farnesylated proteins that have been suggested to be possible FTI targets include RhoB, the centromere-binding proteins CENP-E and CENP-F, and the nuclear lamins [23] . However, to date, no protein has been identified that can directly account for all the actions of FTI, and hence studies aimed at investigating their effects on other farnesylated proteins, such as the IP, are critical for the identification of the major targets of FTI and, secondly, for our detailed understanding of the complete mode of action of FTIs.
In the present study, we sought to establish whether SCH66336 could inhibit IP isoprenylation both in vitro and in vivo and/or whether, analogous to that of Ki-Ras and N-Ras, the IP could become alternatively isoprenylated in the presence of SCH66336. To this end, we generated a series of chimaeric Ha-Ras variants. The experimental approach adopted not only allowed for a direct comparison between the various -CAAX motifs under study, but it was also largely necessitated both by an inability to translate the full-length IP in vitro and the relatively inefficient metabolic labelling of the IP with the isoprene precursor [ 3 H]MVA in vivo, thereby potentially obscuring interpretation of data in the presence of the FTI. In the absence of SCH66336, Ha-Ras WT , Ha-Ras CSLC and Ha-Ras CVIM chimaeras were all preferentially modified by 15-carbon farnesyl isoprenoids both in vitro and in vivo. Consistent with previous studies [14] , changing the terminal serine residue of Ha-Ras to leucine rendered Ha-Ras CVLL a substrate for geranylgeranyl modification in vitro and in vivo, while mutation of the critical acceptor cysteine of Ha-Ras CSLC to Ha-Ras SSLC completely abolished isoprenylation. In the presence of SCH66336, HaRas WT and Ha-Ras CSLC isoprenylation was completely inhibited, suggesting that, unlike Ki-Ras and N-Ras, the C-terminal regions of both Ha-Ras (-CVLS) and IP (-CSLC) do not undergo alternative geranylgeranylation either in vitro or in vivo. As expected, inclusion of SCH66336 had no effect on isoprenylation of the control Ha-Ras SSLC or on the geranylgeranylated Rac 1, Ha-Ras CVLL sequence either in vitro or in vivo. However, SCH66336 resulted in a marked increase in isoprenylation of Ha-Ras CVIM , confirming that, although SCH66336 inhibits farnesylation of the variant HaRas CVIM , it can become alternatively geranylgeranylated in the presence of FTI, and thus serves as a GGTase 1 substrate in vitro and in vivo.
Hence, taken together, these data confirm that the -CSLC motif corresponding to the -CaaX motif of the IP supports the efficient isoprenylation of Ha-Ras and that, unlike the -CVIM motif (naturally found associated with Ki-Ras4B), farnesylation of the -CSLC motif is completely inhibited by SCH66336, and does not undergo alternative geranylgeranylation in the presence of this FTI. Hence, in view of the recognized functional requirement for isoprenylation by the IPs from a range of species [11, 12, 15] , coupled with the observed effects of SCH66336 on IP signalling and function reported herein, it is likely that the IP is a direct target of SCH66336 inhibition which may, in turn, contribute to the more diverse actions of FTIs other than Ras targeting. Whether the therapeutic use of SCH66336 can impair IP-mediated cellular processes in vivo or in human subjects is of course currently unknown. However, it is indeed noteworthy that the IC 50 values for cAMP generation (IC 50 0.27-0.62 nM) and [Ca 2+ ] i mobilization (IC 50 26.6-48.3 nM) are significantly lower than typical plasma concentrations that are reported to be greater than 1 µM in patients receiving 200 mg of SCH66336 twice daily [36] . In view of this and the data presented herein, the effect of SCH66336 on IPsignalling and function in human subjects remains to be critically addressed at the detailed molecular level.
